-
Mashup Score: 0
AbstractAims. Using Scandinavian population-based registries, we assessed risk of stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose - 3 year(s) ago
AbstractAims. In atrial fibrillation (AF) patients 150 mg b.i.d. dabigatran is the standard dose, yet guidelines recommend 110 mg b.i.d. when bleeding risk is h
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose - 3 year(s) ago
AbstractAims. In atrial fibrillation (AF) patients 150 mg b.i.d. dabigatran is the standard dose, yet guidelines recommend 110 mg b.i.d. when bleeding risk is h
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
In this Scandinavian study of >200k #AFib patients initiating oral #anticoagulation, #dabigatran, #apixaban & #rivaroxaban had similar rates of #stroke/SE as patients initiating #warfarin. #wondrmedical #EHJQCCO https://t.co/zwxdapTnik